News


    CHERISH director Dr. Bruce Schackman presented at the National Drug Abuse Treatment Clinical Trials Network (CTN) Annual Scientific Meeting on April 12, 2016. The CTN is a NIDA-funded multi-site research project to determine the effectiveness of behavioral, pharmacological, and integrated treatment interventions across a broad range of community-based treatment settings and diversified patient populations. Dr. […]

    Read the full story

    The 2016 cycle of pilot grant funding is open for applications! Applicants must be affiliated with one of the CHERISH collaborating institutions, Weill Cornell Medicine, Boston Medical Center, University of Pennsylvania or University of Miami Miller School of Medicine. Priority consideration will be given to new investigators, and investigators new to the field (e.g. health […]

    Read the full story

    Karen Lasser, MD, MPH and Yuhua Bao, PhD Awarded Inaugural CHERISH Pilot Grants.   Dr. Lasser’s pilot grant proposes to evaluate economic and health outcomes for a primary care-based HCV treatment program in a patient-centered medical home. The treatment model is based on the chronic care model including a multidisciplinary team with physician, nursing, social […]

    Read the full story

    The National Institutes of Health (NIH) recently released an announcement outlining funding priorities for health economics research. The announcement confirms that health economics methods can be instrumental in promoting the NIH mission to improve health and is an integral part of the interdisciplinary science that NIH supports. It goes on to clarify that NIH will prioritize […]

    Read the full story

    On December 8th, CHERISH Director Dr. Bruce Schackman, delivered a presentation at the NIDA-funded located at the New York University College of Nursing. CDUHR Co-director and CHERISH Center Advisory Board Member Dr. Sherry Deren welcomed Dr. Schackman, who presented an overview of the mission, goals, and organization of CHERISH. Dr. Schackman highlighted the Methodology Consultation […]

    Read the full story

    The high costs of treating the more than 7 million people with a substance use disorder may be daunting to public and private payers. The costs of not treating them may be even higher, especially if you consider the costs of failing to screen for and treat HIV and hepatitis C in this population. Sorting […]

    Read the full story